{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:50:47Z","timestamp":1761630647333,"version":"3.40.4"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T00:00:00Z","timestamp":1366070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T00:00:00Z","timestamp":1366070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s10067-013-2252-0","type":"journal-article","created":{"date-parts":[[2013,4,15]],"date-time":"2013-04-15T06:40:01Z","timestamp":1366008001000},"page":"743-753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Side effects of TNF-\u03b1 blockers in patients with psoriatic arthritis: evidences from literature studies"],"prefix":"10.1007","volume":"32","author":[{"given":"Rosario","family":"Peluso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Cafaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Iervolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Ambrosino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gelsy","family":"Lupoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo Nicola Dario","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,16]]},"reference":[{"issue":"1","key":"2252_CR1","first-page":"49","volume":"59","author":"R Scarpa","year":"2007","unstructured":"Scarpa R, Peluso R, Atteno M (2007) Clinical presentation of psoriatic arthritis. Reumatismo 59(1):49\u201351","journal-title":"Reumatismo"},{"issue":"83","key":"2252_CR2","first-page":"21","volume":"36","author":"PS Helliwell","year":"2009","unstructured":"Helliwell PS (2009) Established psoriatic arthritis: clinical aspects. J Rheumatol 36(83):21\u201323","journal-title":"J Rheumatol"},{"issue":"12","key":"2252_CR3","first-page":"2638","volume":"30","author":"R Scarpa","year":"2003","unstructured":"Scarpa R, Cosentini E, Manguso F, Oriente A, Peluso R, Atteno M, Ayala F, D'Arienzo A, Oriente P (2003) Clinical and genetic aspects of psoriatic arthritis \"sine psoriasis\". J Rheumatol 30(12):2638\u20132640","journal-title":"J Rheumatol"},{"issue":"1","key":"2252_CR4","first-page":"137","volume":"35","author":"R Scarpa","year":"2008","unstructured":"Scarpa R, Cuocolo A, Peluso R, Atteno M, Gisonni P, Iervolino S, Di Minno MN, Nicolai E, Salvatore M, del Puente A (2008) Early psoriatic arthritis: the clinical spectrum. J Rheumatol 35(1):137\u2013141","journal-title":"J Rheumatol"},{"key":"2252_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3899\/jrheum.090217","volume":"83","author":"R Scarpa","year":"2009","unstructured":"Scarpa R, Atteno M, Costa L, Peluso R, Iervolino S, Caso F, Del Puente A (2009) Early psoriatic arthritis. J Rheumatol Suppl 83:26\u201327","journal-title":"J Rheumatol Suppl"},{"key":"2252_CR6","volume-title":"Seronegative polyarthritis","author":"V Wright","year":"1976","unstructured":"Wright V, Moll JMH (1976) Seronegative polyarthritis. North Holland Publishing Company, Amsterdam"},{"key":"2252_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/art.1780210603","volume":"21","author":"V Wright","year":"1978","unstructured":"Wright V (1978) Seronegative polyarthritis: a unified concept. Arthritis Rheum 21:619\u2013633","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2252_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2004.06.013","volume":"52","author":"P Mease","year":"2005","unstructured":"Mease P, Goffe BS (2005) Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 52(1):1\u201319","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2252_CR9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(2):14\u201317","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2252_CR10","first-page":"60","volume":"8","author":"GG Krueger","year":"2002","unstructured":"Krueger GG (2002) Clinical features of psoriatic arthritis. Am J Manag Care 8(6):60\u201370","journal-title":"Am J Manag Care"},{"issue":"1","key":"2252_CR11","first-page":"47","volume":"19","author":"AM Tobin","year":"2005","unstructured":"Tobin AM, Kirby B (2005) TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. Bio Drugs 19(1):47\u201357","journal-title":"Bio Drugs"},{"issue":"4","key":"2252_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10067-009-1340-7","volume":"29","author":"M Atteno","year":"2010","unstructured":"Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29(4):399\u2013403","journal-title":"Clin Rheumatol"},{"issue":"5","key":"2252_CR13","first-page":"700","volume":"30","author":"C Joyau","year":"2012","unstructured":"Joyau C, Veyrac G, Dixneuf V, Jolliet P (2012) Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 30(5):700\u2013706","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"2252_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1556\/OH.2011.28987","volume":"152","author":"G Nagy","year":"2011","unstructured":"Nagy G, Luk\u00e1cs K, Sziray A, Fazekas K, Flori\u00e1n A, Tam\u00e1si L, K\u00e1rolyi Z (2011) Adverse events during biological therapy\u2014focusing on dermatological side-effects. Orv Hetil 152(6):212\u2013220","journal-title":"Orv Hetil"},{"issue":"1","key":"2252_CR15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2310\/7750.2008.07095","volume":"13","author":"C Kirshen","year":"2009","unstructured":"Kirshen C, Kanigsberg N (2009) Alopecia areata following adalimumab. J Cutan Med Surg 13(1):48\u201350","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"2252_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2174\/157488611798280915","volume":"6","author":"B Marasini","year":"2011","unstructured":"Marasini B, Cozzaglio L, Belloli L, Massarotti M, Ughi N, Pedrazzoli P (2011) Metastatic melanoma in a young woman treated with TNF-alpha inhibitor for psoriatic arthritis: a case report. Curr Drug Saf 6(4):275\u2013276","journal-title":"Curr Drug Saf"},{"issue":"3","key":"2252_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","volume":"156","author":"HH Lee","year":"2007","unstructured":"Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, R\u00f6wert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M (2007) Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 156(3):486\u2013491","journal-title":"Br J Dermatol"},{"issue":"1","key":"2252_CR18","first-page":"5","volume":"66","author":"I Zidi","year":"2011","unstructured":"Zidi I, Bartegi A, Ben AN (2011) Dermatologic adverse events: golimumab, friend or foe? Pharmazie 66(1):5\u201310","journal-title":"Pharmazie"},{"issue":"8","key":"2252_CR19","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"WG Dixon","year":"2006","unstructured":"Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54(8):2368\u20132376","journal-title":"Arthritis Rheum"},{"key":"2252_CR20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","volume":"83","author":"S Tsiodras","year":"2008","unstructured":"Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP (2008) Fungal infections complicating tumor necrosis factor blockade therapy. Mayo Clin Proc 83:181\u2013194","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2252_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrrheum.2009.279","volume":"6","author":"SY Kim","year":"2010","unstructured":"Kim SY, Solomon DH (2010) Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 6(3):165\u2013174","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"2252_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2009.146","volume":"301","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7):737\u2013744","journal-title":"JAMA"},{"issue":"2","key":"2252_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1756-185X.2009.01393.x","volume":"12","author":"P Suwannalai","year":"2009","unstructured":"Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S (2009) The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Int J Rheum Dis 12(2):118\u2013124","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"2252_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10067-011-1903-2","volume":"31","author":"C Lydakis","year":"2012","unstructured":"Lydakis C, Ioannidou D, Koumpa I, Giannikaki E, Thalassinos E, Krasoudaki E, Miyakis S (2012) Development of lepromatous leprosy following etanercept treatment for arthritis. Clin Rheumatol 31(2):395\u2013398","journal-title":"Clin Rheumatol"},{"issue":"1\u20132","key":"2252_CR25","first-page":"23","volume":"137","author":"M Kouba","year":"2012","unstructured":"Kouba M, Rudolph SE, Hrdlicka P, Zuber MA (2012) Hepatitis-B reactivation during treatment with tumor necrosis factor-\u03b1 blocker adalimumab in a patient with psoriasis arthritis. Dtsch Med Wochenschr 137(1\u20132):23\u201326","journal-title":"Dtsch Med Wochenschr"},{"issue":"11","key":"2252_CR26","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.3899\/jrheum.081324","volume":"36","author":"SJ Chung","year":"2009","unstructured":"Chung SJ, Kim JK, Park MC, Park YB, Lee SK (2009) Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 36(11):2416\u20132420","journal-title":"J Rheumatol"},{"issue":"4","key":"2252_CR27","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jbspin.2010.12.001","volume":"78","author":"H Liot\u00e9","year":"2011","unstructured":"Liot\u00e9 H, Liot\u00e9 F (2011) Role for interferon-gamma release assays in latent tuberculosis screening before TNF-\u03b1 antagonist therapy. Joint Bone Spine 78(4):352\u2013357","journal-title":"Joint Bone Spine"},{"issue":"51\u201352","key":"2252_CR28","first-page":"2051","volume":"96","author":"L Zimmerli","year":"1994","unstructured":"Zimmerli L, N\u00fcesch R, Elzi L (1994) Update on tuberculosis: interferon-gamma assays. Praxis (Bern 1994) 96(51\u201352):2051\u20132057","journal-title":"Praxis (Bern 1994)"},{"key":"2252_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3899\/jrheum.120252","volume":"89","author":"A Sanduzzi","year":"2012","unstructured":"Sanduzzi A, Bocchino M, Atteno M, Costa L, Ponticiello A, Matarese A, Span\u00f2 A, Bruner V, Peluso R, Aquino MM, Del Puente A, Scarpa R (2012) Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-\u03b1 blockers for psoriatic arthritis. J Rheumatol Suppl 89:82\u201385","journal-title":"J Rheumatol Suppl"},{"issue":"8","key":"2252_CR30","first-page":"914","volume":"10","author":"MB Chang","year":"2011","unstructured":"Chang MB, Sri JC, Driscoll M, Gaspari AA (2011) Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers. J Drugs Dermatol 10(8):914\u2013916","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"2252_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0001-7310(10)70014-4","volume":"101","author":"X Bordas","year":"2010","unstructured":"Bordas X, Mart\u00edn-Sala S (2010) Etanercept and chronic infection by HCV and HBV. Actas Dermosifiliogr 101(1):82\u201387","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"2252_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3109\/15569527.2010.551302","volume":"30","author":"MJ Cruz","year":"2011","unstructured":"Cruz MJ, Baudrier T, Ferreira O, Azevedo F (2011) Herpes zoster at the site of infliximab infusion: case report. Cutan Ocul Toxicol 30(3):236\u2013238","journal-title":"Cutan Ocul Toxicol"},{"issue":"11","key":"2252_CR33","first-page":"277","volume":"68","author":"A Izumi","year":"2009","unstructured":"Izumi A (2009) Varicella zoster virus infection in patients taking the TNF-alpha inhibitor, etanercept: coincidence or causal? Hawaii Med J 68(11):277\u2013278","journal-title":"Hawaii Med J"},{"issue":"3","key":"2252_CR34","first-page":"271","volume":"33","author":"G Buccoliero","year":"2010","unstructured":"Buccoliero G, Lonero G, Romanelli C, Loperfido P, Resta F (2010) Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-alpha agent in a psoriatic arthritis patient. New Microbiol 33(3):271\u2013274","journal-title":"New Microbiol"},{"issue":"5","key":"2252_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jinf.2010.02.009","volume":"60","author":"T Kelesidis","year":"2010","unstructured":"Kelesidis T, Salhotra A, Fleisher J, Uslan DZ (2010) Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections? J Infect 60(5):386\u2013396","journal-title":"J Infect"},{"issue":"1","key":"2252_CR36","first-page":"124","volume":"27","author":"CE Papagoras","year":"2009","unstructured":"Papagoras CE, Argyropoulou MI, Voulgari PV, Vrabie I, Zikou AK, Drosos AA (2009) A case of Brucella spondylitis in a patient with psoriatic arthritis receiving infliximab. Clin Exp Rheumatol 27(1):124\u2013127","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"2252_CR37","first-page":"57","volume":"9","author":"QA Kamili","year":"2010","unstructured":"Kamili QA, Menter A (2010) Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol 9(1):57\u201360","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"2252_CR38","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/ard.2007.081513","volume":"67","author":"EJ Cepeda","year":"2008","unstructured":"Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD (2008) The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 67(5):710\u2013712","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2252_CR39","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11926-012-0260-8","volume":"14","author":"WH Boehncke","year":"2012","unstructured":"Boehncke WH, Boehncke S (2012) Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep 14(4):343\u2013348","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"2252_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11739-011-0704-6","volume":"7","author":"MN Di Minno","year":"2012","unstructured":"Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G (2012) TNF-\u03b1 blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis. Intern Emerg Med 7(2):97\u201398","journal-title":"Intern Emerg Med"},{"issue":"3","key":"2252_CR41","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1161\/ATVBAHA.110.214585","volume":"31","author":"MN Di Minno","year":"2011","unstructured":"Di Minno MN, Lervolino S, Peluso R, Scarpa R, Di Minno G, CaRRDs study group (2011) Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-\u03b1 blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 31(3):705\u2013712","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"2252_CR42","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/ajh.2012.12","volume":"25","author":"K Angel","year":"2012","unstructured":"Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D (2012) Effect of 1-year anti-TNF-\u03b1 therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 25(6):644\u2013650","journal-title":"Am J Hypertens"},{"issue":"5","key":"2252_CR43","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1055\/s-0032-1306433","volume":"38","author":"MN Di Minno","year":"2012","unstructured":"Di Minno MN, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R, Scarpa R, Di Minno G (2012) Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost 38(5):497\u2013505","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2252_CR44","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1472-8206.2010.00872.x","volume":"25","author":"K Angel","year":"2011","unstructured":"Angel K, Provan SA, Hammer HB, Mowinckel P, Kvien TK, Atar D (2011) Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundam Clin Pharmacol 25(4):511\u2013517","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"2252_CR45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1529-8019.2008.01217.x","volume":"22","author":"J Channual","year":"2009","unstructured":"Channual J, Wu JJ, Dann FJ (2009) Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 22(1):61\u201373","journal-title":"Dermatol Ther"},{"issue":"1","key":"2252_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/rheumatology\/kes242","volume":"52","author":"A Russolillo","year":"2013","unstructured":"Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N, Di Minno MN (2013) Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 52(1):62\u201367","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2252_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/acr.21711","volume":"65","author":"MN Di Minno","year":"2013","unstructured":"Di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, Di Minno G (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 65(1):141\u2013147","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"2252_CR48","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1177\/039463201002300334","volume":"23","author":"F Ursini","year":"2010","unstructured":"Ursini F, Succurro E, Grembiale A, Rudi S, Grembiale RD, Arturi F (2010) Sudden progression from impaired glucose tolerance to type 2 diabetes after discontinuation of administration of anti-tumor necrosis factor-alpha antibody infliximab. Int J Immunopathol Pharmacol 23(3):961\u2013963","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"12","key":"2252_CR49","first-page":"2440","volume":"33","author":"E Spanakis","year":"2006","unstructured":"Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT (2006) Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 33(12):2440\u20132446","journal-title":"J Rheumatol"},{"key":"2252_CR50","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/01.CIR.0000017216.41471.DF","volume":"105","author":"F de Clari","year":"2002","unstructured":"de Clari F, Salani I, Safwan E, Giannacco A (2002) Sudden death in a patient without heart failure after a single infusion of 200\u00a0mg infliximab: does TNF-\u03b1 have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation 105:183","journal-title":"Circulation"},{"issue":"10","key":"2252_CR51","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","volume":"138","author":"HJ Kwon","year":"2003","unstructured":"Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138(10):807\u2013811","journal-title":"Ann Intern Med"},{"key":"2252_CR52","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000055916","volume":"68","author":"Y Mandi","year":"2000","unstructured":"Mandi Y, Hogye M, Talha L et al (2000) Cytokine production and antibodies against heat shock protein 60 in cardiomyopathies of different origins. Pathobiology 68:150\u2013158","journal-title":"Pathobiology"},{"key":"2252_CR53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/026765910101600110","volume":"16","author":"DB Sanders","year":"2001","unstructured":"Sanders DB, Larson DF, Hunter K et al (2001) Comparison of tumor necrosis factor-\u03b1 effect on the expression of iNOS in macrophages and cardiac myocytes. Perfusion 16:67\u201374","journal-title":"Perfusion"},{"key":"2252_CR54","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1006\/jmcc.2001.1388","volume":"33","author":"SB Haudek","year":"2001","unstructured":"Haudek SB, Bryant DD, Giroir BP (2001) Differential regulation of myocardial NK kappa B following acute or chronic TNF-\u03b1 exposure. J Mol Cell Cardiol 33:1263\u20131271","journal-title":"J Mol Cell Cardiol"},{"key":"2252_CR55","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1152\/ajpheart.2001.280.5.H2281","volume":"280","author":"T Kadokami","year":"2001","unstructured":"Kadokami T, McTiernan CF, Kubota T et al (2001) Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. Am J Physiol Heart Circ Physiol 280:2281\u20132291","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2252_CR56","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1006\/jmcc.2001.1428","volume":"33","author":"T Tanaka","year":"2001","unstructured":"Tanaka T, Kanda T, McManus BM et al (2001) Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-\u03b1. J Mol Cell Cardiol 33:1627\u20131635","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"2252_CR57","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jbspin.2006.02.010","volume":"73","author":"B Saint Marcoux","year":"2006","unstructured":"Saint Marcoux B, De Bandt M, CRI (Club Rhumatismes et Inflammation) (2006) Vasculitides induced by TNF-alpha antagonists: a study in 39 patients in France. Joint Bone Spine 73(6):710\u2013713","journal-title":"Joint Bone Spine"},{"issue":"1","key":"2252_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3904\/kjim.2007.22.1.63","volume":"22","author":"MJ Kang","year":"2007","unstructured":"Kang MJ, Kim MS, Choi EH, Lee KE, Kim YK, Choi HJ (2007) Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis. Korean J Intern Med 22(1):63\u201366","journal-title":"Korean J Intern Med"},{"issue":"4","key":"2252_CR59","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1055\/s-2007-1016443","volume":"62","author":"K El-Hag","year":"2008","unstructured":"El-Hag K, Dercken HG, Prenzel R, H\u00f6lzle E (2008) Drug-induced alveolitis associated with infliximab\/azathioprine therapy. Pneumologie 62(4):204\u2013208","journal-title":"Pneumologie"},{"issue":"5","key":"2252_CR60","first-page":"109","volume":"68","author":"S Jinno","year":"2009","unstructured":"Jinno S, Pulido S, Pien BC (2009) First reported United States case of Legionella pneumophila serogroup 1 pneumonia in a patient receiving anti-tumor necrosis factor-alpha therapy. Hawaii Med J 68(5):109\u2013112","journal-title":"Hawaii Med J"},{"issue":"8","key":"2252_CR61","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10067-009-1169-0","volume":"28","author":"S Dubey","year":"2009","unstructured":"Dubey S, Kerrigan N, Mills K, Scott DG (2009) Bronchospasm associated with anti-TNF treatment. Clin Rheumatol 28(8):989\u2013992","journal-title":"Clin Rheumatol"},{"issue":"4","key":"2252_CR62","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.semarthrit.2008.11.003","volume":"39","author":"A Massara","year":"2010","unstructured":"Massara A, Cavazzini L, La Corte R, Trotta F (2010) Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new \u201cclass effect\u201d paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 39(4):313\u2013319","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2252_CR63","first-page":"471","volume":"26","author":"E Toussirot","year":"2008","unstructured":"Toussirot E, Pertuiset E, Kantelip B, Wendling D (2008) Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 26(3):471\u2013475","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"2252_CR64","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/rheumatology\/kep046","volume":"48","author":"CI Daien","year":"2009","unstructured":"Daien CI, Monnier A, Claudepierre P et al (2009) Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 48(8):883\u2013886","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2252_CR65","first-page":"91","volume":"28","author":"P Men\u00e8","year":"2010","unstructured":"Men\u00e8 P, Franeta AJ, Conti G, Stoppacciaro A, Chimenz R, Fede A, Gallizzi R, Fede C (2010) Extracapillary glomerulonephritis during etanercept treatment for juvenile psoriatic arthritis. Clin Exp Rheumatol 28(1):91\u201393","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"2252_CR66","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.nephro.2010.05.003","volume":"6","author":"M Sacqu\u00e9p\u00e9e","year":"2010","unstructured":"Sacqu\u00e9p\u00e9e M, Rouleau V, Cantin JF, Quirin N, Doussy Y, Val\u00e9ry JC, Picu C, Tivollier JM (2010) Active WHO class IV lupus nephritis in a patient treated with etanercept for a psoriasic arthritis. Nephrol Ther 6(6):537\u2013540","journal-title":"Nephrol Ther"},{"issue":"6","key":"2252_CR67","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2007.078840","volume":"67","author":"GH Louie","year":"2008","unstructured":"Louie GH, Chitkara P, Ward MM (2008) Relapse of sarcoidosis upon treatment with etanercept. Ann Rheum Dis 67(6):896\u2013898","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2252_CR68","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/art.22238","volume":"55","author":"MA Gonzalez-Lopez","year":"2006","unstructured":"Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC, Fernandez-Llaca H, Rodriguez-Valverde V (2006) Development of sarcoidosis during etanercept therapy. Arthritis Rheum 55(5):817\u2013820","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2252_CR69","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/art.22351","volume":"55","author":"FD O\u2019Shea","year":"2006","unstructured":"O\u2019Shea FD, Marras TK, Inman RD (2006) Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum 55(6):978\u2013981","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2252_CR70","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000275676","volume":"220","author":"F Dhaille","year":"2010","unstructured":"Dhaille F, Viseux V, Caudron A et al (2010) Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology 220(3):234\u2013237","journal-title":"Dermatology"},{"issue":"11","key":"2252_CR71","first-page":"2313","volume":"34","author":"G Sturfelt","year":"2007","unstructured":"Sturfelt G, Christensson B, Bynke G, Saxne T (2007) Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J Rheumatol 34(11):2313\u20132314","journal-title":"J Rheumatol"},{"issue":"1","key":"2252_CR72","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5414\/CPP49038","volume":"49","author":"S Hagel","year":"2011","unstructured":"Hagel S, Bruns T, Theis B, Herrmann A, Stallmach A (2011) Subacute liver failure induced by adalimumab. Int J Clin Pharmacol Ther 49(1):38\u201340","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9","key":"2252_CR73","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1136\/ard.2009.112136","volume":"69","author":"J Sokolove","year":"2010","unstructured":"Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE, CORRONA, Investigators (2010) Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 69(9):1612\u20131617","journal-title":"Ann Rheum Dis"},{"key":"2252_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.12.025","author":"M Ghabril","year":"2013","unstructured":"Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M, U.S. Drug-Induced Liver Injury Network (2013) Liver injury from tumor necrosis factor-\u03b1 antagonists: analysis of 34 cases. Clin Gastroenterol Hepatol. doi:10.1016\/j.cgh.2012.12.025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2252_CR75","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1136\/ard.2009.116194","volume":"69","author":"M Seitz","year":"2010","unstructured":"Seitz M, Reichenbach S, M\u00f6ller B, Zwahlen M, Villiger PM, Dufour JF (2010) Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Ann Rheum Dis 69(6):1148\u20131150","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2252_CR76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/039463200902200234","volume":"22","author":"M Massarotti","year":"2009","unstructured":"Massarotti M, Marasini B (2009) Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol 22(2):547\u2013549","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"12","key":"2252_CR77","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44(12):2862\u20132869","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2252_CR78","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jaad.2005.05.039","volume":"54","author":"SA Sukal","year":"2006","unstructured":"Sukal SA, Nadiminti L, Granstein RD (2006) Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 54(1):160\u2013164","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2252_CR79","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/archneurol.2009.11","volume":"66","author":"P Lozeron","year":"2009","unstructured":"Lozeron P, Denier C, Lacroix C, Adams D (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66(4):490\u2013497","journal-title":"Arch Neurol"},{"issue":"9","key":"2252_CR80","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","volume":"44","author":"WH Robinson","year":"2001","unstructured":"Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor \u03b1 antagonism: by what mechanisms could tumor necrosis factor \u03b1 antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44(9):1977\u20131983","journal-title":"Arthritis Rheum"},{"key":"2252_CR81","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/ard.2006.066787","volume":"66","author":"I Simsek","year":"2007","unstructured":"Simsek I, Erdem H, Pay S, Sobaci G, Dinc A (2007) Optic neuritis occurring with anti-tumour necrosis factor a therapy. Ann Rheum Dis 66:1255\u20131258","journal-title":"Ann Rheum Dis"},{"key":"2252_CR82","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.optm.2005.07.003","volume":"76","author":"MT Bhatti","year":"2005","unstructured":"Bhatti MT, Schmitt NJ, Beatty RL (2005) Acute inflammatory demyelinating optic neuritis: current concepts in diagnosis and management. Optometry 76:526\u2013535","journal-title":"Optometry"},{"key":"2252_CR83","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1345\/aph.1G279","volume":"39","author":"R Noguera-Pons","year":"2005","unstructured":"Noguera-Pons R, Borras-Blasco J, Romero-Crespo I, Anton-Torres R, Navarro-Ruiz A, Gonzalez-Ferrandez JA (2005) Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother 39:2131\u20132135","journal-title":"Ann Pharmacother"},{"key":"2252_CR84","first-page":"985","volume":"120","author":"R Foroozan","year":"2002","unstructured":"Foroozan R, Buono LM, Sergott RC, Savino PJ (2002) Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol 120:985\u2013987","journal-title":"Arch Ophthalmol"},{"key":"2252_CR85","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archopht.122.5.793","volume":"122","author":"LJ Mejico","year":"2004","unstructured":"Mejico LJ (2004) Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol 122:793\u2013794","journal-title":"Arch Ophthalmol"},{"key":"2252_CR86","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jaapos.2005.12.002","volume":"10","author":"T Tauber","year":"2006","unstructured":"Tauber T, Turetz J, Barash J, Avni I, Morad Y (2006) Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS 10:26\u201329","journal-title":"J AAPOS"},{"key":"2252_CR87","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jns.2006.01.012","volume":"244","author":"JH Chung","year":"2006","unstructured":"Chung JH, Van Stavern GP, Frohman LP, Turbin RE (2006) Adalimumab-associated optic neuritis. J Neurol Sci 244:133\u2013136","journal-title":"J Neurol Sci"},{"key":"2252_CR88","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1378\/chest.62.1.71","volume":"62","author":"AL Goldman","year":"1972","unstructured":"Goldman AL, Braman SS (1972) Isoniazid: a review with emphasis on adverse effects. Chest 62:71\u201377","journal-title":"Chest"},{"key":"2252_CR89","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","volume":"47","author":"BW Van Oosten","year":"1996","unstructured":"Van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BME et al (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531\u20131534","journal-title":"Neurology"},{"key":"2252_CR90","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS\/MRI Analysis Group","year":"1999","unstructured":"The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS\/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457\u2013465","journal-title":"Neurology"},{"key":"2252_CR91","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0923-2494(97)87239-2","volume":"148","author":"A Cope","year":"1997","unstructured":"Cope A, Ettinger R, McDevitt H (1997) The role of TNF-alpha and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 148:307\u2013312","journal-title":"Res Immunol"},{"issue":"1","key":"2252_CR92","first-page":"149","volume":"58","author":"AN Theofilopoulos","year":"1999","unstructured":"Theofilopoulos AN, Lawson BR (1999) Tumor necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 58(1):149\u2013155","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2252_CR93","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.58.2008.i32","volume":"58","author":"G Kollias","year":"1999","unstructured":"Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) The function of tumor necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Ann Rheum Dis 58(1):32\u201339","journal-title":"Ann Rheum Dis"},{"key":"2252_CR94","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1084\/jem.185.9.1573","volume":"185","author":"AP Cope","year":"1997","unstructured":"Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD et al (1997) Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 185:1573\u20131584","journal-title":"J Exp Med"},{"issue":"1","key":"2252_CR95","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/ard.58.2008.i121","volume":"58","author":"C Lock","year":"1999","unstructured":"Lock C, Oksenberg J, Steinman L (1999) The role of TNFa and lymphotoxin in demyelinating disease. Ann Rheum Dis 58(1):121\u2013128","journal-title":"Ann Rheum Dis"},{"key":"2252_CR96","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ana.410230405","volume":"23","author":"KW Selmaj","year":"1988","unstructured":"Selmaj KW, Raine CS (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339\u2013346","journal-title":"Ann Neurol"},{"key":"2252_CR97","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/(SICI)1098-1136(20000215)29:4<366::AID-GLIA7>3.0.CO;2-Y","volume":"29","author":"A Bitsch","year":"2000","unstructured":"Bitsch A, Kuhlmann T, da Costa C, Bunkowski S, Polak T, Bruck W (2000) Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 29:366\u2013375","journal-title":"Glia"},{"key":"2252_CR98","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0140-6736(87)92863-7","volume":"1","author":"HS Panitch","year":"1987","unstructured":"Panitch HS, Hirsch RL, Haley AS, Johnson KP (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1:893\u2013895","journal-title":"Lancet"},{"issue":"4","key":"2252_CR99","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86(4):242\u2013251","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2252_CR100","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","volume":"37","author":"MF Costa","year":"2008","unstructured":"Costa MF, Said NR, Zimmermann B (2008) Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37(6):381\u2013387","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"2252_CR101","first-page":"1283","volume":"9","author":"D Levine","year":"2010","unstructured":"Levine D, Switlyk SA, Gottlieb A (2010) Cutaneous lupus erythematosus and anti-TNF-alpha therapy: a case report with review of the literature. J Drugs Dermatol 9(10):1283\u20131287","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"2252_CR102","first-page":"2287","volume":"30","author":"SJ Jarrett","year":"2003","unstructured":"Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P (2003) Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 30(10):2287\u20132291","journal-title":"J Rheumatol"},{"issue":"7","key":"2252_CR103","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","volume":"146","author":"R Klein","year":"2010","unstructured":"Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J (2010) Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 146(7):780\u2013784","journal-title":"Arch Dermatol"},{"key":"2252_CR104","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2212-4","author":"A Mounach","year":"2011","unstructured":"Mounach A, Rezqi A, Nouijai A, Ghozlani I, Achemlal L, Maghraoui AE, Bezza A (2011) Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. Rheumatol Int. doi:10.1007\/s00296-011-2212-4","journal-title":"Rheumatol Int"},{"issue":"2","key":"2252_CR105","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","volume":"41","author":"R Perez-Alvarez","year":"2011","unstructured":"Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, Brito-Zeron P, Bosch X, Ramos-Casals M (2011) Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 41(2):256\u2013264","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"2252_CR106","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.arbres.2010.05.011","volume":"47","author":"L Gifre","year":"2011","unstructured":"Gifre L, Ruiz-Esquide V, Xaubet A, G\u00f3mez-Puerta JA, Hern\u00e1ndez MV, Sanmart\u00ed R (2011) Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch Bronconeumol 47(4):208\u2013212","journal-title":"Arch Bronconeumol"},{"key":"2252_CR107","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","volume":"43","author":"PJ Charles","year":"2000","unstructured":"Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383\u20132390","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2252_CR108","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/art.10876","volume":"48","author":"L De Rycke","year":"2003","unstructured":"De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F (2003) Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum 48(4):1015\u20131023","journal-title":"Arthritis Rheum"},{"key":"2252_CR109","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1136\/ard.2009.117762","volume":"69","author":"X Mariette","year":"2010","unstructured":"Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P et al (2010) Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 69:400\u2013408","journal-title":"Ann Rheum Dis"},{"key":"2252_CR110","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/rheumatology\/kem214","volume":"46","author":"J Sheppard","year":"2007","unstructured":"Sheppard J, Raza K, Buckley CD (2007) Skin cancer in psoriatic arthritis treated with anti-TNF therapy. Rheumatology 46:1622\u20131623","journal-title":"Rheumatology"},{"key":"2252_CR111","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jaad.2004.07.031","volume":"51","author":"RS Fryrear","year":"2004","unstructured":"Fryrear RS, Wiggins AK, Sangueza O, Yosipovitch G (2004) Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol 51:1026","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2252_CR112","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.stomax.2009.07.002","volume":"110","author":"A Rousseau","year":"2009","unstructured":"Rousseau A, Taberne R, Siberchicot F, Fricain JC, Zwetyenga N (2009) Cancer of the cheek in a patient under etanercept. Rev Stomatol Chir Maxillofac 110(5):306\u2013308","journal-title":"Rev Stomatol Chir Maxillofac"},{"issue":"5","key":"2252_CR113","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jaad.2003.11.044","volume":"50","author":"AC Esser","year":"2004","unstructured":"Esser AC, Abril A, Fayne S, Doyle JA (2004) Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 50(5):75\u201377","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2252_CR114","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1067\/mjd.2001.117725","volume":"45","author":"KJ Smith","year":"2001","unstructured":"Smith KJ, Skelton HG (2001) Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 45(6):953\u2013956","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2252_CR115","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1371\/journal.pone.0048991","volume":"7","author":"G Moulis","year":"2012","unstructured":"Moulis G, Sommet A, B\u00e9n\u00e9 J, Montastruc F, Sailler L, Montastruc JL, Lapeyre-Mestre M (2012) Cancer risk of anti-TNF-\u03b1 at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One 7(11):489\u2013491","journal-title":"PLoS One"},{"issue":"2","key":"2252_CR116","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1124\/jpet.301.2.418","volume":"301","author":"B Scallon","year":"2002","unstructured":"Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301(2):418\u2013426","journal-title":"J Pharmacol Exp Ther"},{"key":"2252_CR117","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1159\/000117709","volume":"216","author":"C Antoniou","year":"2008","unstructured":"Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD (2008) Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 216:364\u2013365","journal-title":"Dermatology"},{"key":"2252_CR118","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000117708","volume":"216","author":"J Santos-Juanes","year":"2008","unstructured":"Santos-Juanes J, Coto-Segura P, Mallo S, Galache C, Soto J (2008) Multiple eruptive dermatofibromas in a patient receiving efalizumab. Dermatology 216:363","journal-title":"Dermatology"},{"key":"2252_CR119","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","volume":"69","author":"WD DeWys","year":"1980","unstructured":"DeWys WD, Begg C, Lavin PT, Bandt PR, Bennett JM, Bertino JR et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491\u2013497","journal-title":"Am J Med"},{"key":"2252_CR120","first-page":"1505","volume":"19","author":"R Roubenoff","year":"1992","unstructured":"Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellmann DB (1992) Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor J Rheumatol 19:1505\u20131510","journal-title":"Possible association with tumor necrosis factor J Rheumatol"},{"key":"2252_CR121","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/art.1780390707","volume":"39","author":"LC Rall","year":"1996","unstructured":"Rall LC, Rosen CJ, Dolnikowski G, Hartman WJ, Lundgren N, Abad LW et al (1996) Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor \u03b1. Arthritis Rheum 39:1115\u20131124","journal-title":"Arthritis Rheum"},{"key":"2252_CR122","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/ard.56.5.326","volume":"56","author":"R Munro","year":"1997","unstructured":"Munro R, Capell H (1997) Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. Ann Rheum Dis 56:326\u2013329","journal-title":"Ann Rheum Dis"},{"key":"2252_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1753-4887.1993.tb03045.x","volume":"51","author":"R Roubenoff","year":"1993","unstructured":"Roubenoff R, Rall LC (1993) Humoral mediation of changing body composition during aging and chronic inflammation. Nutr Rev 51:1\u201311","journal-title":"Nutr Rev"},{"key":"2252_CR124","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/rheumatology\/36.4.444","volume":"36","author":"R Westhovens","year":"1997","unstructured":"Westhovens R, Nijs J, Taelman V, Dequeker J (1997) Body composition in rheumatoid arthritis. Br J Rheumatol 36:444\u2013448","journal-title":"Br J Rheumatol"},{"key":"2252_CR125","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1079\/PNS2001110","volume":"60","author":"SW Coppack","year":"2001","unstructured":"Coppack SW (2001) Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349\u2013356","journal-title":"Proc Nutr Soc"},{"key":"2252_CR126","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/ard.2004.028670","volume":"64","author":"K Briot","year":"2005","unstructured":"Briot K, Garnero P, Le Henanff A, Dougados M, Roux C (2005) Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor a treatment. Ann Rheum Dis 64:1137\u20131140","journal-title":"Ann Rheum Dis"},{"key":"2252_CR127","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/ard.62.4.347","volume":"62","author":"F Allali","year":"2003","unstructured":"Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondylarthropthy treated with antitumour necrosis factor alpha. Ann Rheum Dis 62:347\u2013349","journal-title":"Ann Rheum Dis"},{"key":"2252_CR128","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/593039","author":"A Lutf","year":"2012","unstructured":"Lutf A, Hammoudeh M (2012) Weight gain and hair loss during anti-TNF therapy. Int J Rheumatol. doi:10.1155\/2012\/593039","journal-title":"Int J Rheumatol"},{"issue":"4","key":"2252_CR129","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1529-8019.2011.01439.x","volume":"24","author":"LD Renzo","year":"2011","unstructured":"Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A, Esposito M, Tiberti S, Chimenti S, DE Lorenzo A (2011) Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-\u03b1 treatment. Dermatol Ther 24(4):446\u2013451","journal-title":"Dermatol Ther"},{"issue":"3","key":"2252_CR130","first-page":"199","volume":"58","author":"B Seriolo","year":"2006","unstructured":"Seriolo B, Paolino S, Sulli A, Cutolo M (2006) Are there any positive effects of TNF-alpha blockers on bone metabolism? Reumatismo 58(3):199\u2013205","journal-title":"Reumatismo"},{"issue":"4","key":"2252_CR131","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1468-3083.2010.03770.x","volume":"25","author":"M Ferran","year":"2011","unstructured":"Ferran M, Calvet J, Almirall M, Pujol RM, Maym J (2011) Alopecia areata as another immune-mediated disease developed in patients treated with tumor necrosis factor-\u03b1 blocker agents. J Eur Acad Dermatol Venereol 25(4):479\u2013484","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2252_CR132","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0301-2115(98)00252-8","volume":"83","author":"S Daher","year":"1999","unstructured":"Daher S, Fonseca F, Ribero O, Musatti C, Gerbase de Lima M (1999) Tumor necrosis factor during pregnancy. Eur J Obstet Gyn R B 83:77\u201379","journal-title":"Eur J Obstet Gyn R B"},{"key":"2252_CR133","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijgo.2004.08.020","volume":"88","author":"XW Yu","year":"2005","unstructured":"Yu XW, Yan CF, Jin HL, Li X (2005) Tumor necrosis factor receptor 1 expression and early spontaneous abortion. Int J Gynecol and Obstet 88:44\u201344","journal-title":"Int J Gynecol and Obstet"},{"issue":"2","key":"2252_CR134","first-page":"155","volume":"52","author":"CD Chambers","year":"2005","unstructured":"Chambers CD (2005) Safety of anti-TNF alpha medications in pregnancy. J Am Acad Dermatol 52(2):155\u201308","journal-title":"J Am Acad Dermatol"},{"key":"2252_CR135","first-page":"241","volume":"30","author":"EF Chakravarty","year":"2003","unstructured":"Chakravarty EF, Sanchez-Yamamoto D, Bush TE (2003) The use of disease modifying anti-rheumatic drugs in women with rheumatoid arthritis of child bearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 30:241\u2013246","journal-title":"J Rheumatol"},{"key":"2252_CR136","doi-asserted-by":"publisher","first-page":"S349","DOI":"10.1002\/art.20743","volume":"52","author":"BE Joven","year":"2005","unstructured":"Joven BE, Garcia-Gonzales AJ, Ruiz T et al (2005) Pregnancy in women receiving anti TNF therapy. Experience in Spain. Arthritis Rheum 52:S349","journal-title":"Arthritis Rheum"},{"key":"2252_CR137","first-page":"1014","volume":"33","author":"JD Carter","year":"2006","unstructured":"Carter JD, Valeriano J, Vasey B (2006) Tumor necrosis factor alpha inhibition and VATER association: a causal relationship? J Rheumatol 33:1014\u20131017","journal-title":"J Rheumatol"},{"key":"2252_CR138","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/rheumatology\/kel400","volume":"46","author":"CH Roux","year":"2007","unstructured":"Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2007) Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-\u03b1 therapy. Rheumatology 46:695\u2013698","journal-title":"Rheumatology"},{"issue":"1","key":"2252_CR139","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","volume":"76","author":"JM Berthelot","year":"2009","unstructured":"Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Liot\u00e9 F, Goeb V, Aza\u00efs I, Martin A, Pallot-Prades B, Maugars Y, Mariette X, CRI (Club Rhumatismes et Inflammation) (2009) Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76(1):28\u201334","journal-title":"Joint Bone Spine"},{"key":"2252_CR140","first-page":"533","volume":"3","author":"BP Giroir","year":"1992","unstructured":"Giroir BP, Peppel K, Siva M, Beutler B (1992) The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors. Eur Cytokine Netw 3:533\u2013537","journal-title":"Eur Cytokine Netw"},{"key":"2252_CR141","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1191\/096032700678815765","volume":"19","author":"G Treacy","year":"2000","unstructured":"Treacy G (2000) Using an autologous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti TNF alpha monoclonal antibody. Hum Exp Toxicol 19:226\u2013228","journal-title":"Hum Exp Toxicol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2252-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-013-2252-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2252-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2252-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:44:38Z","timestamp":1745988278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-013-2252-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,16]]},"references-count":141,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["2252"],"URL":"https:\/\/doi.org\/10.1007\/s10067-013-2252-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2013,4,16]]},"assertion":[{"value":"18 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}